When shares of PolyMedica (PLMD), trading at 11 1/2 in early November, weakened in recent weeks and hit 5 on Mar. 23, medical analyst Sharon di Stefano of Ryan Beck, an investment firm in Livingston, N.J., contacted not only management but large PolyMedica shareholders to find out why the stock had crashed. She found no fundamental reason to justify the fall. "They weren't selling, and they may in fact be buyers at these levels," says di Stefano. The stock edged up to 6 1/16 the next day.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.
- Fewest Jobless Claims Since 1973 Show Firm U.S. Job Market
- Germans Are Going Wild for a Show Set During the Dawn of the Nazis
- Greenwich Mansion Listings Pulled to Wait for a Better Day
- The U.K.'s $86 Billion Pension Problem Is About to Solve Itself
- U.S. Stocks Climb With Treasuries as Dollar Slides: Markets Wrap